Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

In vivo models of multiple system atrophy

Identifieur interne : 000399 ( France/Analysis ); précédent : 000398; suivant : 000400

In vivo models of multiple system atrophy

Auteurs : Pierre-Olivier Fernagut [États-Unis] ; Imad Ghorayeb [France] ; Elsa Diguet [France] ; François Tison [France]

Source :

RBID : ISTEX:629EA02B9C0F28D38EF308EC2BB64C31881343C4

English descriptors

Abstract

Multiple system atrophy (MSA) is a sporadic adult‐onset neurodegenerative disorder of unknown etiology clinically characterized by a combination of parkinsonian, pyramidal, and cerebellar signs. Levodopa‐unresponsive parkinsonism is present in 80% of MSA cases, and this dominant clinical presentation (MSA‐P) is associated with a combined degeneration of the substantia nigra pars compacta and the striatum in anatomically related areas. The limited knowledge of the pathophysiology of MSA and the lack of therapeutic strategies prompted the development of lesion models reproducing striatonigral degeneration, the substrate of levodopa‐unresponsive parkinsonism in MSA‐P. This method was carried out first in rats with two different stereotaxic strategies using either two neurotoxins (“double toxin–double lesion”) or a single neurotoxin (“single toxin–double lesion”). Double‐lesioned rat models showed severe motor impairment compared to those with a single nigral or striatal lesion and helped to mimic different stages of the disease. Systemic models were also developed in mice and primates using the nigral toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and the striatal toxin 3‐nitropropionic (3‐NP). In mice, although MPTP reduced the subsequent sensitivity to 3‐NP in a sequential lesion, simultaneous nigral and striatal insults were shown to exacerbate striatal damage. MPTP‐treated monkeys displayed a significant worsening of parkinsonism and a loss of levodopa‐responsiveness after the appearance of hindlimb dystonia and striatal lesion formation induced by subsequent 3‐NP intoxication. The different species and intoxication paradigms used will be useful to investigate functional changes in substantia nigra and striatum and to define neuroprotective, neurorestorative, or symptomatic therapeutic strategies. © 2005 Movement Disorder Society

Url:
DOI: 10.1002/mds.20541


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:629EA02B9C0F28D38EF308EC2BB64C31881343C4

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">In vivo models of multiple system atrophy</title>
<author>
<name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
</author>
<author>
<name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name>
</author>
<author>
<name sortKey="Diguet, Elsa" sort="Diguet, Elsa" uniqKey="Diguet E" first="Elsa" last="Diguet">Elsa Diguet</name>
</author>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:629EA02B9C0F28D38EF308EC2BB64C31881343C4</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20541</idno>
<idno type="url">https://api.istex.fr/document/629EA02B9C0F28D38EF308EC2BB64C31881343C4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F90</idno>
<idno type="wicri:Area/Istex/Curation">000F90</idno>
<idno type="wicri:Area/Istex/Checkpoint">002294</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Fernagut P:in:vivo:models</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16092092</idno>
<idno type="wicri:Area/PubMed/Corpus">002F35</idno>
<idno type="wicri:Area/PubMed/Curation">002F35</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003097</idno>
<idno type="wicri:Area/Ncbi/Merge">001377</idno>
<idno type="wicri:Area/Ncbi/Curation">001377</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001377</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Fernagut P:in:vivo:models</idno>
<idno type="wicri:Area/Main/Merge">004F71</idno>
<idno type="wicri:Area/Main/Curation">003886</idno>
<idno type="wicri:Area/Main/Exploration">003886</idno>
<idno type="wicri:Area/France/Extraction">000399</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">In vivo models of multiple system atrophy</title>
<author>
<name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of California Los Angeles, Los Angeles, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Neurophysiologie, Université Victor Segalen Bordeaux2, Bordeaux Cedex</wicri:regionArea>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Diguet, Elsa" sort="Diguet, Elsa" uniqKey="Diguet E" first="Elsa" last="Diguet">Elsa Diguet</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Neurophysiologie, Université Victor Segalen Bordeaux2, Bordeaux Cedex</wicri:regionArea>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Neurophysiologie, Université Victor Segalen Bordeaux2, Bordeaux Cedex</wicri:regionArea>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
<wicri:noRegion>Bordeaux Cedex</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">S12</biblScope>
<biblScope unit="supplement">S12</biblScope>
<biblScope unit="page" from="S57">S57</biblScope>
<biblScope unit="page" to="S63">S63</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">629EA02B9C0F28D38EF308EC2BB64C31881343C4</idno>
<idno type="DOI">10.1002/mds.20541</idno>
<idno type="ArticleID">MDS20541</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>3‐NP</term>
<term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (pathology)</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP</term>
<term>MPTP Poisoning (metabolism)</term>
<term>MSA‐P</term>
<term>Macaca fascicularis</term>
<term>Mice</term>
<term>Multiple System Atrophy (genetics)</term>
<term>Multiple System Atrophy (metabolism)</term>
<term>Multiple System Atrophy (pathology)</term>
<term>Oxidopamine (metabolism)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (genetics)</term>
<term>Parkinsonian Disorders (pathology)</term>
<term>Point Mutation (genetics)</term>
<term>Rats</term>
<term>Substantia Nigra (metabolism)</term>
<term>Substantia Nigra (pathology)</term>
<term>alpha-Synuclein (genetics)</term>
<term>alpha-Synuclein (metabolism)</term>
<term>alpha‐synuclein</term>
<term>levodopa‐unresponsive parkinsonism</term>
<term>multiple system atrophy</term>
<term>pathophysiology</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Oxidopamine</term>
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
<term>Point Mutation</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Corpus Striatum</term>
<term>MPTP Poisoning</term>
<term>Multiple System Atrophy</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Corpus Striatum</term>
<term>Multiple System Atrophy</term>
<term>Parkinsonian Disorders</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Macaca fascicularis</term>
<term>Mice</term>
<term>Rats</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Multiple system atrophy (MSA) is a sporadic adult‐onset neurodegenerative disorder of unknown etiology clinically characterized by a combination of parkinsonian, pyramidal, and cerebellar signs. Levodopa‐unresponsive parkinsonism is present in 80% of MSA cases, and this dominant clinical presentation (MSA‐P) is associated with a combined degeneration of the substantia nigra pars compacta and the striatum in anatomically related areas. The limited knowledge of the pathophysiology of MSA and the lack of therapeutic strategies prompted the development of lesion models reproducing striatonigral degeneration, the substrate of levodopa‐unresponsive parkinsonism in MSA‐P. This method was carried out first in rats with two different stereotaxic strategies using either two neurotoxins (“double toxin–double lesion”) or a single neurotoxin (“single toxin–double lesion”). Double‐lesioned rat models showed severe motor impairment compared to those with a single nigral or striatal lesion and helped to mimic different stages of the disease. Systemic models were also developed in mice and primates using the nigral toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and the striatal toxin 3‐nitropropionic (3‐NP). In mice, although MPTP reduced the subsequent sensitivity to 3‐NP in a sequential lesion, simultaneous nigral and striatal insults were shown to exacerbate striatal damage. MPTP‐treated monkeys displayed a significant worsening of parkinsonism and a loss of levodopa‐responsiveness after the appearance of hindlimb dystonia and striatal lesion formation induced by subsequent 3‐NP intoxication. The different species and intoxication paradigms used will be useful to investigate functional changes in substantia nigra and striatum and to define neuroprotective, neurorestorative, or symptomatic therapeutic strategies. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>France</li>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Californie">
<name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
</region>
</country>
<country name="France">
<noRegion>
<name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name>
</noRegion>
<name sortKey="Diguet, Elsa" sort="Diguet, Elsa" uniqKey="Diguet E" first="Elsa" last="Diguet">Elsa Diguet</name>
<name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000399 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000399 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:629EA02B9C0F28D38EF308EC2BB64C31881343C4
   |texte=   In vivo models of multiple system atrophy
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024